KRAS and colorectal cancer: On the other hand, the 20050181 study showed significant OS and PFS benefits of panitumumab (Pmab) plus FOLFIRI vs. FOLFIRI for KRAS-wild colorectal cancer, whereas no OS benefit was observed for KRAS-mutant colorectal cancer [12] (Table 1).